Cat. No.: HY-N2995

Poricoic acid A

(Synonyms: Poricoic acid A(F))

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Poricoic acid A can be isolated from Poria cocos. Poricoic acid A is an orally active anti-tumor agent. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Poricoic acid A also attenuatea fibroblast activation and abnormal extracellular matrix remodeling in renal fibrosis by activating AMPK and inhibiting Smad3. Poricoic acid A significantly reduces the magnitude of rise in serum creatinine and urea levels in rat model when combined with Melatonin. Poricoic acid A ameliorates renal fibrosis and podocyte injury by attenuating oxidative stress and inflammation through regulating NF-κB and Nrf2 in IRI rodent model in combination with Melatonin.

For research use only. We do not sell to patients.

Purity: 99.19%
CAS No.: 137551-38-3
Formula: C₃₁H₄₆O₅
Molecular Weight:498.69

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Poricoic acid A Chemical Structure

CAS No.: 137551-38-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All NF-κB Isoforms :

All AMPK Isoforms :

All TGF-beta/Smad Isoforms :

Smad1
Smad3

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>100 μM Compound: 1a	Cytotoxicity in human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity in human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 21250700]
AZ-521 cell line	IC₅₀	>100 μM Compound: 1a	Cytotoxicity in human AZ-521 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity in human AZ-521 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 21250700]
B16	IC₅₀	48.01 μg/mL Compound: 8	Cytotoxicity against mouse B16 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTS assay Cytotoxicity against mouse B16 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTS assay	[PMID: 39026645]
CCRF-CEM	IC₅₀	>40 μM Compound: 22	Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 27808511]
DU-145	IC₅₀	>100 μM Compound: 1a	Cytotoxicity in human DU145 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity in human DU145 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 21250700]
HL-60	IC₅₀	>40 μM Compound: 22	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 27808511]
HL-60	IC₅₀	38 μM Compound: 1a	Cytotoxicity in human HL60 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity in human HL60 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 21250700]
HL-60	IC₅₀	38 μM Compound: 7	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 19746919]
K562	IC₅₀	>40 μM Compound: 22	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 27808511]
MOLT-4	IC₅₀	>40 μM Compound: 22	Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay	[PMID: 27808511]
OVCAR-3	IC₅₀	>100 μM Compound: 1a	Cytotoxicity in human OVCAR3 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity in human OVCAR3 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 21250700]
PANC-1	IC₅₀	>100 μM Compound: 1a	Cytotoxicity in human PANC1 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity in human PANC1 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 21250700]
SK-BR-3	IC₅₀	>100 μM Compound: 1a	Cytotoxicity in human SK-BR-3 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity in human SK-BR-3 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 21250700]

In Vitro

Poricoic acid A (10 μM) protects against hypoxia/reoxygenation (H/R)-induced injury in cultured renal NRK-52E cells^[2].
Poricoic acid A (5-10 μM, 24 h) has inhibitory effects on NRK-49F viability dose-dependently^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[2]

Cell Line:

Renal NRK-52E cells
Concentration:

10 μM
Incubation Time:

24 h
Result:

Reduced the level of NF-κB that transferred into the nucleus after H/R.
Resulted in stronger inhibitory effect on inflammatory pathway when combined with Melatonin.
Upregulated the HO-1 level that was reduced due to H/R.

In Vivo

Poricoic acid A (10 mg/kg/day, i.g., day 2 to 13 after reperfusion) significantly mitigates the increase in levels of serum creatinine and urea in male SD rats^[2].
Poricoic acid A (5-20 mg/kg, p.o., 1-2 w) ameliorates hyoertension and anaemia as well as improves kidney function in Nx-induced CKD rats^[3].
Poricoic acid A (5-20 mg/kg, p.o., 1-2 w) significantly reduced renal fibrosis in UUO rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male IRI SD rats^[2]
Dosage:

10 mg/kg/day
Administration:

Intragastric (i.g.), day 2 to 13 after reperfusion
Result:

Significantly downregulated pro-fibrotic Gas6 protein level, and combined therapy with Melatonin performed better.
Significantly ameliorated the activation of NF-κB pathway.
Significantly attenuated the expression of ED-1 and CD3 in renal interstitium compared with IRI group.
Mitigated the downregulation of Nrf2 and its downstream targets in IRI rats.
Markedly reduced the deposition of collagen I and collagen III in renal interstitium.

Animal Model:

Nx-induced CKD rats^[3]
Dosage:

5, 10, 20 mg/kg
Administration:

Oral gavage (p.o.)
Result:

Ameliorated polyuria, elevated blood pressure, increased serum urea and creatinine levesl, reduced creatinine clearance and lowered body weight.
Suppressed aberrant synthesis and enhanced degradation of ECM in Nx rats.
Activated AMPK and suppressed TGF-β1/Smad3 pathway.

Chemical Information

CAS No. 137551-38-3
Appearance Solid
Molecular Weight 498.69
Formula C₃₁H₄₆O₅
Color White to off-white
SMILES

C[C@]12[C@@]([C@]([C@H](C(O)=O)CCC(C(C)C)=C)([H])[C@H](O)C1)(CC=C3C2=CC[C@@H](C(C)=C)[C@]3(C)CCC(O)=O)C
Synonyms

Poricoic acid A(F)
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Int J Mol Sci

Poricoic Acid A Attenuates Osteoarthritis Progression by Stabilizing PTEN and Suppressing PI3K/AKT Signaling. [Abstract]

2026 Feb 14;27(4):1835. PMID: 41751971

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (200.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0053 mL

10.0263 mL

20.0525 mL

5 mM

0.4011 mL

2.0053 mL

4.0105 mL

10 mM

0.2005 mL

1.0026 mL

2.0053 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Dong H, et al. Enrichment and separation of antitumor triterpene acids from the epidermis of Poria cocos by pH-zone-refining counter-current chromatography and conventional high-speed counter-current chromatography. J Sep Sci. 2015 Jun;38(11):1977-82. [Content Brief]

[2]. Chen DQ, et al. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Free Radic Biol Med. 2019 Apr;134:484-497. [Content Brief]

[3]. Dan-Qian Chen, et al., Poricoic acid A activates AMPK to attenuate fibroblast activation and abnormal extracellular matrix remodelling in renal fibrosis. Phytomedicine, 2020, 72.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0053 mL	10.0263 mL	20.0525 mL	50.1313 mL
	5 mM	0.4011 mL	2.0053 mL	4.0105 mL	10.0263 mL
	10 mM	0.2005 mL	1.0026 mL	2.0053 mL	5.0131 mL
	15 mM	0.1337 mL	0.6684 mL	1.3368 mL	3.3421 mL
	20 mM	0.1003 mL	0.5013 mL	1.0026 mL	2.5066 mL
	25 mM	0.0802 mL	0.4011 mL	0.8021 mL	2.0053 mL
	30 mM	0.0668 mL	0.3342 mL	0.6684 mL	1.6710 mL
	40 mM	0.0501 mL	0.2507 mL	0.5013 mL	1.2533 mL
	50 mM	0.0401 mL	0.2005 mL	0.4011 mL	1.0026 mL
	60 mM	0.0334 mL	0.1671 mL	0.3342 mL	0.8355 mL
	80 mM	0.0251 mL	0.1253 mL	0.2507 mL	0.6266 mL
	100 mM	0.0201 mL	0.1003 mL	0.2005 mL	0.5013 mL

Keywords

Poricoic acid A

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Poricoic acid A

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Poricoic acid A

All NF-κB Isoforms

All AMPK Isoforms

All TGF-beta/Smad Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Poricoic acid A Related Classifications

HY-N2995 Related Classifications